

Corp. Reg. No. 556756-8521
Date: November 21 2022

Idogen's scientific adviser Jan Holgersson strengthens the company's Board of Directors

Idogen AB (publ) announced today that Jan Holgersson, who has served for several years as scientific adviser to the company, has agreed to strengthen the company's Board of Directors in the role as co-opted Board member.

Jan Holgersson is a professor of Transplant Immunology at Gothenburg University, the Medical Director of the Tissue Typing and Stem Cell Laboratories at Sahlgrenska University Hospital in Gothenburg, where he was also formerly the Head of Clinical Immunology and Transfusion Medicine. His research focuses on understanding the immunological mechanisms that underlie the rejection of transplanted organs and tissues. Another important initiative has been supporting the development of diagnostics for detection and semiquantification of antibodies against the ABH blood group antigens and other tissue antigens (non-HLA).

Jan Holgersson is also Chairman of the Board of VERIGRAFT AB, a Swedish biotech company.

Jan has been part of the company's efforts at a detailed survey of the mechanisms of action for the company's technology platform.

Agneta Edberg, Chairman of the Board of Idogen: "With his solid experience in clinical immunology, Professor Jan Holgersson has worked for many years in both academia and medical care, as well as in roles at the strategic level in the industry, and he is therefore a highly valuable addition to the company now that we are in the clinical phase. We have had a very positive collaboration with Jan as an adviser on our Scientific Advisory Board, and we are now taking the next step by co-opting Jan onto the Board. We are pleased to welcome him."

"In the last few years, I have had the privilege of working closely with the company in an advisory role, and it feels natural to now take greater responsibility for the strategic development of the company's technology platform from both a scientific and a medical perspective," says Professor Jan Holgersson.

For further information, please contact:

Christina Herder, Acting CEO, Idogen AB

Tel: +46 70 374 71 56

E-mail: christina.herder@idogen.com

Certified Adviser:

Vator

The information was submitted for publication, through the agency of the contact person set out above, at 08:07 CET on November 21, 2022.

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced program, IDO 8 – now in its clinical phase – is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. For these hemophiliac patients, there is significant medical need for restoring the clinical effects of their treatment with factor VIII. This is a unique market positioning that over the long term could replace immune tolerance induction (ITI) treatments, with significant market potential. The planned IDO 8 clinical trial will validate the

PRESSMEDDELANDE IDOGEN AB



company's technology platform and facilitate a range of other applications in fields such as organ transplants (IDO T) and autoimmune diseases (IDO AID). More information about Idogen is available via <https://www.idogen.com>